Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Advertisement
Nature Medicine (2022)
Metrics details
Subgroup analysis of the EMPEROR-Preserved clinical trial of the glucose-lowering drug empagliflozin in chronic heart failure with left ventricular ejection fraction (LVEF) >40% found improved clinical outcomes in the cohort of patients with LVEF ≥50%. This is, to our knowledge, the first time a drug therapy has been unequivocally demonstrated to benefit this patient population.
This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
73,83 €
only 6,15 € per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.
Talha, K. M. & Butler, J. Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction. Clin. Cardiol. 45, S31–S39 (2022). A review of the history of classification of heart failure with mildly reduced and preserved ejection fraction and advances in their treatment.
Article Google Scholar
Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451–1461 (2021). This paper reports the main findings of the EMPEROR-Preserved clinical trial.
Article CAS Google Scholar
Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413–1424 (2020). This paper reports the main findings of the EMPEROR-Reduced clinical trial.
Article CAS Google Scholar
Heidenreich, P. A. et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145, e895–e1032 (2022). A review article that presents the latest comprehensive clinical guidelines on managing heart failure from the major US cardiology associations.
Google Scholar
Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015). This paper reports the main findings of the EMPA-REG OUTCOME clinical trial.
Article CAS Google Scholar
Download references
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Anker, S. D. et al. Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved. Nat. Med. https://doi.org/10.1038/s41591-022-02041-5 (2022).
Reprints and Permissions
Empagliflozin benefits in patients with heart failure and preserved ejection fraction. Nat Med (2022). https://doi.org/10.1038/s41591-022-02050-4
Download citation
Published: 09 December 2022
DOI: https://doi.org/10.1038/s41591-022-02050-4
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
Advertisement
© 2022 Springer Nature Limited
Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.